CollPlant Biotechnologies Ltd.

CLGN

$0.34

-0.61%

N/A-$0.00

Salud

Biotecnología

NASDAQ

Negociación activa

CollPlant Biotechnologies Ltd. es una empresa de medicina regenerativa y estética que opera en Estados Unidos, Canadá y Europa. La compañía se ...

Análisis fundamental de CLGN

Fortalezas clave

Proprietary plant-based technology for producing recombinant human Type I collagen (rhCollagen), enabling differentiated bioprinting materials and products

Positioned at the intersection of regenerative medicine (3D bioprinting) and medical aesthetics, diversifying end markets

Factores de riesgo

Sustained operating losses and negative net margin (~-33.76% TTM) indicate the business is not yet producing reliable profitability

Weak cash generation and negative/meaningless earnings-based valuation metrics (negative P/E; negative operating cash flow coverage), increasing dependence on external financing

Rentabilidad

Margen neto-3376.35%

Margen operativo-3329.05%

Valoración

PER-0.33x

Ratio corriente2.27

Eficiencia

ROE-160.28%

ROA-143.03%

Análisis Fundamental de CLGN

CollPlant Biotechnologies Ltd. (CLGN) is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues/organs and medical aesthetics. Its core platform is plant-based recombinant human Type I collagen (rhCollagen) produced through proprietary genetic engineering technology, which underpins bioprinting bioinks/matrices and injectable/dermal aesthetic products. The business model is commercialization of enabling materials plus downstream medical products, supported by collaborations with partners across bioprinting ecosystems and healthcare development. From a fundamentals standpoint, the most visible issue is profitability and cash generation. TTM margins are deeply negative: gross margin is about -3.19%, operating margin about -33.29%, EBITDA margin about -30.93%, and net margin about -33.76%. Returns are also sharply negative (ROA ~ -1.43, ROE ~ -1.60), consistent with a company still in development/commercial scaling mode rather than steady-state profitability. Valuation ratios derived from earnings are not meaningful (P/E is negative), and free-cash-flow metrics are unfavorable (free cash flow yield about -2.86% on an enterprise basis; EV/Free Cash Flow ~ -0.21), indicating the market is effectively pricing for future success rather than current earnings power. Balance-sheet liquidity appears comparatively supported: current ratio (TTM) is ~2.27 and quick ratio is ~1.99, suggesting near-term coverage of obligations. However, the company’s cash generation remains weak (operating cash flow coverage ratios are negative and interest coverage is negative), and leverage is moderate (debt-to-equity ~0.54). This combination typically increases reliance on continued funding—whether through operations, capital markets, partnerships, or other financing. Net, CLGN has a potentially defensible platform (collagen sourcing/material manufacturing capability) but currently demonstrates pre-profit execution risk. For long-term investors, the key question is whether clinical/regulatory progress and commercialization can translate into sustained revenue growth and improving margins before additional dilution or funding constraints become dominant.

Fortalezas clave de CLGN

Proprietary plant-based technology for producing recombinant human Type I collagen (rhCollagen), enabling differentiated bioprinting materials and products
Positioned at the intersection of regenerative medicine (3D bioprinting) and medical aesthetics, diversifying end markets
Product portfolio includes bioinks, soft-tissue repair matrices (e.g., Vergenix series), and injectable/implant solutions, which can broaden commercialization pathways
Strategic collaborations with established industry and research partners (e.g., 3D Systems ecosystem, Cellink/BICO, academic institutes, and healthcare/industry participants)
Liquidity indicators are comparatively strong (current ratio ~2.27, quick ratio ~1.99), which can help finance operations through development milestones
Moderate leverage (debt-to-equity ~0.54) relative to many early-stage healthcare developers, reducing immediate balance-sheet distress risk

Factores de riesgo de CLGN

Sustained operating losses and negative net margin (~-33.76% TTM) indicate the business is not yet producing reliable profitability
Weak cash generation and negative/meaningless earnings-based valuation metrics (negative P/E; negative operating cash flow coverage), increasing dependence on external financing
Regulatory and clinical uncertainty common to novel regenerative and implantable/aesthetic medical products, with potential delays or unfavorable outcomes
Manufacturing scale-up and commercialization execution risk for bioprinted matrices, injectables, and implants (quality, consistency, and cost targets)
Working-capital and cash-conversion risk: long cash conversion cycle indicators and receivables turnover patterns (DSO ~218.6 days) can strain liquidity even with acceptable ratios
Dilution risk for shareholders if additional capital is required to fund R&D, clinical/regulatory steps, and commercialization
Macro/industry risk: healthcare spending cycles, reimbursement dynamics, and competitive pressure from established regenerative medicine and aesthetic players
Small-cap liquidity/volatility risk (beta ~0.68, low absolute price and limited market cap), which can amplify drawdowns during financing/clinical news

Capitalización vs ingresos y beneficios

Beneficios

n/a

Ingresos

n/a

Capitalización bursátil

$4.42M

-0.3x

Ratio P/E

11.4x

Ratio P/S

Beneficios e ingresos

Último informen/a

Beneficio por acción (EPS)n/a

Margen bruto-319.28%

Margen neto-3376.35%

Ratio deuda/capital0.54

Puente de rentabilidad (actual vs interanual)

Muestra cómo cambiaron el margen bruto, operativo y neto frente al año anterior.

Historial de ingresos / beneficio neto / FCF (USD B)

Señales de crecimiento de CLGN

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ingresos	—	—	—	—	Plano
EPS diluido	—	—	—	—	Plano
Flujo de caja libre	—	—	—	—	Plano

Rentabilidad de CLGN

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Margen neto	—	-4242.47%	—	—	Plano
Margen operativo	—	-4267.12%	—	—	Plano
ROE	—	—	—	—	Plano

Salud financiera de CLGN

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ratio corriente	—	2.268	—	—	Plano
Ratio rápido	—	1.990	—	—	Plano
Deuda / capital	—	0.542	—	—	Plano

Valoración de CLGN

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
P/E	—	-0.58x	—	—	Plano
P/B	—	1.51x	—	—	Plano

Supply Chain de CLGN

RELATIONS

Upstream

CollPlant Internal Greenhouse OperationsCollPlant cGMP Manufacturing Facility (Rehovot, Israel)Corning IncorporatedNYSE:GLW Thermo Fisher Scientific Inc.NYSE:TMODEKRA SEMerck KGaA (MilliporeSigma)XETRA:MRKSartorius AGXETRA:SRT3

Downstream

STEMCELL Technologies Inc.United Therapeutics CorporationNASDAQ:UTHR Stratasys Ltd.NASDAQ:SSYS 3D Systems CorporationNYSE:DDDCELLINK (BICO Group AB)STO:BICOAbbVie Inc. (via Allergan Aesthetics)NYSE:ABBVArthrex Inc.VergenixSTR Distributors — Netherlands, Turkey, IndiaVergenixFG Distributor — UkraineVergenixFG Distributor — TurkeyVergenix Distributor — Europe Expansion

Proxies

United Therapeutics CorporationNASDAQ:UTHR Organovo Holdings Inc.NASDAQ:ONVO Stratasys Ltd.NASDAQ:SSYSBICO Group ABSTO:BICO

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal